Total submissions: 10
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000041932 | SCV000065628 | benign | not specified | 2009-06-24 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV000041932 | SCV000317213 | benign | not specified | criteria provided, single submitter | clinical testing | ||
Athena Diagnostics | RCV000993543 | SCV001146621 | benign | not provided | 2018-11-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000993543 | SCV001716545 | benign | not provided | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000993543 | SCV001941379 | benign | not provided | 2015-03-03 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003450904 | SCV004182787 | benign | Retinitis pigmentosa 39 | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001273713 | SCV004182788 | benign | Usher syndrome type 2A | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Dept Of Ophthalmology, |
RCV003888410 | SCV004707923 | benign | Retinal dystrophy | 2023-10-01 | criteria provided, single submitter | research | |
Breakthrough Genomics, |
RCV000993543 | SCV005287651 | benign | not provided | criteria provided, single submitter | not provided | ||
Natera, |
RCV001273713 | SCV001457083 | benign | Usher syndrome type 2A | 2020-09-16 | no assertion criteria provided | clinical testing |